GlassScriptPhysician profile
Dana Wade
NPI 1659783330
$7,251.40
in general payments reported to CMS, 2019-2025
40 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $1,671 · 2023: $1,979 · 2024: $1,368 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,526.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $911.96 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $849.71 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $707.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $639.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $577.66 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $488.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $485.55 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $391.80 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $242.95 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $192.15 | 2022-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $143.49 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $139.19 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $119.68 | 2023-2025 | Auvelity |
| Dexcom, INC. | $118.73 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.71 | 2021-2025 | Xifaxan |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.